{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:10:58Z","timestamp":1773659458314,"version":"3.50.1"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Decreased oxygen causes a rapid inhibition of mRNA translation. An important regulatory mechanism of translational repression under hypoxic conditions involves inhibition of the mammalian target of rapamycin (mTOR). mTOR is a target of the phosphatase and tensin homologue detected on chromosome 10 (PTEN)\/phosphatidylinositol 3-kinase\/AKT\/TSC2 pathway, a pathway that is frequently mutated in human cancers. Although hypoxia has been shown to inhibit mTOR activity, we show here that the hypoxia-induced inhibition of mTOR activity is attenuated in cells lacking TSC2 or PTEN, resulting in a higher translation rate even under hypoxic conditions. Comparison of mTOR inhibition by hypoxia alone or in combination with rapamycin showed that prolonged exposure to hypoxia was required to fully inhibit mTOR activity even in wild-type cells. Increased mTOR activity and protein synthesis did not translate into enhanced cell proliferation rates. However, lack of TSC2 resulted in a survival advantage when cells were exposed to hypoxia. Protection against hypoxia-induced cell death due to TSC2 deficiency is rapamycin-resistant, suggesting that TSC2 affects an apoptotic pathway. Tumors derived from TSC2 wild-type cells exhibited a growth delay compared with TSC2-deficient tumors, indicating that enhanced mTOR activity is advantageous in the initial phase of tumor growth. Therefore, failure to inhibit mTOR under oxygen-limiting conditions can be affected by upstream activating mutations and increases the survival and growth of hypoxic tumor cells. (Cancer Res 2006; 66(3): 1561-9)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-3375","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T16:48:20Z","timestamp":1138812500000},"page":"1561-1569","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Mutations in the PI3K\/PTEN\/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic Conditions"],"prefix":"10.1158","volume":"66","author":[{"given":"Fiona","family":"Kaper","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Stanford University, Stanford, California and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"Dornhoefer","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Stanford University, Stanford, California and"},{"name":"2Department of Obstetrics and Gynecology, University of Leipzig, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amato J.","family":"Giaccia","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Stanford University, Stanford, California and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2006,2,1]]},"reference":[{"key":"2022061622135783400_B1","doi-asserted-by":"crossref","unstructured":"Hoeckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst\u20082001;93:266\u201376.","DOI":"10.1093\/jnci\/93.4.266"},{"key":"2022061622135783400_B2","doi-asserted-by":"crossref","unstructured":"Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer\u20082003;3:721\u201332.","DOI":"10.1038\/nrc1187"},{"key":"2022061622135783400_B3","unstructured":"Pettersen E, Juul N, Ronning O. Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res\u20081986;46:4346\u201351."},{"key":"2022061622135783400_B4","doi-asserted-by":"crossref","unstructured":"Koumenis C, Naczki C, Koritzinsky M, et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2\u03b1. Mol Cell Biol\u20082002;22:7405\u201316.","DOI":"10.1128\/MCB.22.21.7405-7416.2002"},{"key":"2022061622135783400_B5","doi-asserted-by":"crossref","unstructured":"Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP\/mTOR. Genes Dev\u20082001;15:807\u201326.","DOI":"10.1101\/gad.887201"},{"key":"2022061622135783400_B6","doi-asserted-by":"crossref","unstructured":"Tinton SA, Buc-Calderon PM. Hypoxia increases the association of 4E-binding protein 1 with the initiation factor 4E in isolated rat hepatocytes. FEBS Lett\u20081999;446:55\u20139.","DOI":"10.1016\/S0014-5793(99)00185-4"},{"key":"2022061622135783400_B7","doi-asserted-by":"crossref","unstructured":"Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem\u20082003;278:29655\u201360.","DOI":"10.1074\/jbc.M212770200"},{"key":"2022061622135783400_B8","doi-asserted-by":"crossref","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev\u20082004;18:1926\u201345.","DOI":"10.1101\/gad.1212704"},{"key":"2022061622135783400_B9","doi-asserted-by":"crossref","unstructured":"Kunz J, Henriquez R, Schneider U, et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell\u20081993;73:585\u201396.","DOI":"10.1016\/0092-8674(93)90144-F"},{"key":"2022061622135783400_B10","doi-asserted-by":"crossref","unstructured":"Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell\u20081994;78:35\u201343.","DOI":"10.1016\/0092-8674(94)90570-3"},{"key":"2022061622135783400_B11","unstructured":"Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1\u03b1 expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res\u20082000;60:1541\u20135."},{"key":"2022061622135783400_B12","doi-asserted-by":"crossref","unstructured":"Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1\u03b1 expression and function by the mammalian target of rapamycin. Mol Cell Biol\u20082002;22:7004\u201314.","DOI":"10.1128\/MCB.22.20.7004-7014.2002"},{"key":"2022061622135783400_B13","doi-asserted-by":"crossref","unstructured":"Chung J, Grammer TC, Lemon KP, et al. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature\u20081994;370:71\u20135.","DOI":"10.1038\/370071a0"},{"key":"2022061622135783400_B14","unstructured":"Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res\u20082000;60:3504\u201313."},{"key":"2022061622135783400_B15","doi-asserted-by":"crossref","unstructured":"Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc Natl Acad Sci U S A\u20082001;98:10314\u20139.","DOI":"10.1073\/pnas.171076798"},{"key":"2022061622135783400_B16","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol\u20082002;4:648\u201357.","DOI":"10.1038\/ncb839"},{"key":"2022061622135783400_B17","doi-asserted-by":"crossref","unstructured":"Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell\u20082003;11:1457\u201366.","DOI":"10.1016\/S1097-2765(03)00220-X"},{"key":"2022061622135783400_B18","doi-asserted-by":"crossref","unstructured":"Li Y, Inoki K, Guan KL. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol\u20082004;24:7965\u201375.","DOI":"10.1128\/MCB.24.18.7965-7975.2004"},{"key":"2022061622135783400_B19","doi-asserted-by":"crossref","unstructured":"Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev\u20082003;17:1829\u201334.","DOI":"10.1101\/gad.1110003"},{"key":"2022061622135783400_B20","doi-asserted-by":"crossref","unstructured":"Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex. Genes Dev\u20082004;18:2893\u2013904.","DOI":"10.1101\/gad.1256804"},{"key":"2022061622135783400_B21","doi-asserted-by":"crossref","unstructured":"Schwarzer R, Tondera D, Arnold W, et al. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene\u20082005;24:1138\u201349.","DOI":"10.1038\/sj.onc.1208236"},{"key":"2022061622135783400_B22","doi-asserted-by":"crossref","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer\u20082002;2:489\u2013501.","DOI":"10.1038\/nrc839"},{"key":"2022061622135783400_B23","doi-asserted-by":"crossref","unstructured":"Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell\u20082005;121:179\u201393.","DOI":"10.1016\/j.cell.2005.02.031"},{"key":"2022061622135783400_B24","doi-asserted-by":"crossref","unstructured":"Mazure NM, Chen EY, Laderoute KR, et al. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase\/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood\u20081997;90:3322\u201331.","DOI":"10.1182\/blood.V90.9.3322"},{"key":"2022061622135783400_B25","doi-asserted-by":"crossref","unstructured":"Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev\u20082000;14:391\u20136.","DOI":"10.1101\/gad.14.4.391"},{"key":"2022061622135783400_B26","doi-asserted-by":"crossref","unstructured":"Radu A, Neubauer V, Akagi T, et al. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol\u20082003;23:6139\u201349.","DOI":"10.1128\/MCB.23.17.6139-6149.2003"},{"key":"2022061622135783400_B27","unstructured":"El-Hashemite N, Walker V, Zhang H, et al. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res\u20082003;63:5173\u20137."},{"key":"2022061622135783400_B28","doi-asserted-by":"crossref","unstructured":"Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol\u20082004;22:2954\u201363.","DOI":"10.1200\/JCO.2004.02.141"},{"key":"2022061622135783400_B29","doi-asserted-by":"crossref","unstructured":"Brugarolas JB, Vazquez F, Reddy A, et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell\u20082003;4:147\u201358.","DOI":"10.1016\/S1535-6108(03)00187-9"},{"key":"2022061622135783400_B30","doi-asserted-by":"crossref","unstructured":"Graeber TG, Peterson JF, Tsai M, et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol\u20081994;14:6264\u201377.","DOI":"10.1128\/mcb.14.9.6264-6277.1994"},{"key":"2022061622135783400_B31","unstructured":"Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am\u20081998;4:218\u201323."},{"key":"2022061622135783400_B32","doi-asserted-by":"crossref","unstructured":"Hammond EM, Denko NC, Dorie MJ, et al. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol\u20082002;22:1834\u201343.","DOI":"10.1128\/MCB.22.6.1834-1843.2002"},{"key":"2022061622135783400_B33","doi-asserted-by":"crossref","unstructured":"Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science\u20081991;253:905\u20139.","DOI":"10.1126\/science.1715094"},{"key":"2022061622135783400_B34","unstructured":"Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res\u20081993;53:5721\u20136."},{"key":"2022061622135783400_B35","doi-asserted-by":"crossref","unstructured":"Coutant A, Rescan C, Gilot D, et al. PI3K-FRAP\/mTOR pathway is critical for hepatocyte proliferation whereas MEK\/ERK supports both proliferation and survival. Hepatology\u20082002;36:1079\u201388.","DOI":"10.1053\/jhep.2002.36160"},{"key":"2022061622135783400_B36","doi-asserted-by":"crossref","unstructured":"Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K\/AKT\/mTOR\/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol\u20082004;287:C281\u201391.","DOI":"10.1152\/ajpcell.00422.2003"},{"key":"2022061622135783400_B37","doi-asserted-by":"crossref","unstructured":"Gao N, Zhang Z, Jiang BH, et al. Role of PI3K\/AKT\/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun\u20082003;310:1124\u201332.","DOI":"10.1016\/j.bbrc.2003.09.132"},{"key":"2022061622135783400_B38","doi-asserted-by":"crossref","unstructured":"Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther\u20082002;1:453\u20138.","DOI":"10.4161\/cbt.1.5.157"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/3\/1561\/2560334\/1561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/3\/1561\/2560334\/1561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:41:11Z","timestamp":1655426471000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/3\/1561\/527180\/Mutations-in-the-PI3K-PTEN-TSC2-Pathway-Contribute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,2,1]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-3375","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}